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Background:Malignant odontogenic tumours (MOTs) arise either de novo from the tooth
forming tissues, their developmental residues or from existing odontogenic epithelial or
mesenchymal neoplasms in the jaws. Their management requires extensive surgery
due to their infiltrative nature and risk of metastasis. There is a need to understand
the clinical and pathological features of MOTs to inform both treatment algorithms and
prognostication. This is an area of diagnostic pathology which presents substantial
difficulties in diagnosis, compounded by inconsistent use of terminology. Thus, this
systematic review aimed to describe the clinical and pathological features of MOTs
with a view to consolidating the literature and defining problematic areas in diagnosis
and classification.
Methods: An electronic database search was conducted in Web of Science,
PubMed/Medline, and Embase. Additionally, the grey literature and reference lists of
selected papers searched for completeness. Nine hundred and sixty articles were initially
identified. Following removal of duplicates and application of inclusion/exclusion criteria,
312 articles were included for qualitative analysis.
Results: The 312 articles encompassed a total of 507 patients with most
lesions located within the mandible (74.3%). The most common first histological
diagnosis was ameloblastic carcinoma (25.7% of all diagnoses), but there is
considerable variation in how and when various diagnostic terms are used, and
several misdiagnoses were reported. An initial benign diagnosis was made in 24.7%
of patients, followed by a later malignant diagnosis and in this sub-group, the most
common benign first diagnosis was ameloblastoma (42.4%). Cervical lymph nodes
were the most common site of metastasis (9.3% of patients). With respect to distant
metastasis (DM), the lungs were the most common organ affected (11.2% of DM
patients) with metastasising ameloblastoma the most commonly reported tumour
which metastasised to the lungs. Overall, 26.8% of patients developed recurrence.
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Conclusion: Overall, the quality of the literature on MOTs is poor. This review of the
literature has highlighted variations in diagnostic terms and criteria which has resulted in
areas of confusion with potential for misdiagnosis. This consolidation of primary data has
identified key areas for targeted research including further discussion on the malignant
potential of ameloblastoma.
Keywords: odontogenic tumour, malignant odontogenic tumour, radiographic features, treatment, recurrence
INTRODUCTION
Malignant odontogenic tumours (MOTs) arise either de novo
from the tooth forming tissues, their developmental residues or
from existing odontogenic epithelial or mesenchymal neoplasms
in the jaws and malignant transformation of benign odontogenic
tumours (OTs) [1, 2]. Most MOTs are neoplasms consisting
of malignant epithelium, including ameloblastic carcinoma and
primary intraosseous squamous cell carcinoma (PIOSCC) [2–
5] (Figure 1). The frequency of MOTs varies across geographic
regions comprising 0.3–0.4% of all OTs in Brazil [6, 7], 1.1–
1.3% in Nigeria and Mexico [5, 8] and accounting for 5.7%
in the United Kingdom [3]. However, the published case
series are very variable, as some are based on referral cases
rather than a true representation of population incidence, and
odontomes are variably included, which can dramatically affect
the overall proportions of individual tumours [3]. A variety
of growth patterns have been reported from slow-growing to
highly aggressive tumours with local recurrence and metastasis,
most commonly to cervical lymph nodes and lungs [2, 9,
10]. Therefore, management may require extensive surgery and
adjuvant therapies such as radiotherapy and/or chemotherapy.
MOTs present several challenges in terms of classification,
diagnosis and prognosis. The World Health Organisation
(WHO) updated their Classification of Head and Neck Tumours
FIGURE 1 | Exemplar histology of the commonest malignant odontogenic tumours. (A) Ameloblastic carcinoma. This was a maxillary lesion and the patient presented
with a lymph node metastasis within 6 months. (B) Primary Intraosseous Carcinoma NOS (historically synonymous with PIOSCC) from the angle of the mandible. (C)
Clear Cell Odontogenic Carcinoma, which showed re-arrangement of the EWSR1 gene. (D) Ameloblastic Fibrosarcoma.
in 2017, simplifying the MOT classification and adding the
newly described tumour, Sclerosing Odontogenic Carcinoma
[11]. Diagnostic criteria for MOTs have developed and changed
over several iterations of the WHO classification, but for some
entities, these criteria are still rather vague. Furthermore, genetic
profiles and biomarkers have also been described for some
tumour entities in recent years [11, 12]. The diagnostic challenges
of MOTs are due to similar histopathological appearances to
their benign counterparts and limitations of incisional biopsies
not being representative of the entire tumour [3], leading to
misdiagnosis in the first histopathological sample.
Currently, due to the limited number of a wide variety of
reported cases and their classification, neither outcome nor
prognosis can be confidently outlined. Thus, there is a need
to understand the clinical and pathological features of MOTs
to inform both treatment algorithms and prognostication. This
systematic review aims to determine these features with a view to
consolidate and explain the problems in the literature, delineate
current problems and inform future research.
METHODS
A preliminary literature search was conducted by one of the
authors (MD) to inform the search strategy. Keywords were
based on the current and historic classification of tumour names
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to include studies with differences in nomenclature but those that
may still fulfil the inclusion criteria.
An electronic search of the following databases was
conducted; Web of Science, PubMed/MEDLINE and
Embase from 1946 or 1974 respectively to August 2020
with the following key words: (odontogenic carcinoma) OR
(malignant ameloblastoma) OR (metastasizing/metastasising
ameloblastoma) OR (ameloblastic carcinoma) OR (sclerosing
odontogenic carcinoma) OR (primary intraosseous carcinoma)
OR (primary intraosseous squamous cell carcinoma) OR
(malignant variants of odontogenic tumours) OR (malignant
changes in odontogenic cysts) OR (odontogenic cyst malignancy)
OR (clear cell odontogenic carcinoma) OR (ghost cell
odontogenic carcinoma) OR (malignant keratocyst) OR
(malignant keratocystic odontogenic tumour) OR (odontogenic
sarcoma) OR (ameloblastic fibrosarcoma) OR (ameloblastic
odonto-dentinosarcoma) OR (ameloblastic odontosarcoma)
OR (ameloblastic fibrodentinosarcoma) OR (ameloblastic
fibroodontosarcoma) OR (odontogenic carcinosarcoma) OR
(malignant changes in odontogenic cysts). Additionally, a
search of the grey literature was undertaken through several
sources including google scholar, professional pathology society
webpages, government guidelines and reports and relevant
hospital publications. This was supplemented by screening
entire reference lists of included studies. This search strategy
conforms to the preferred reporting items for systematic
reviews and meta-analysis (PRISMA) and is registered on
PROSPERO (CRD42021248757).
Parameters were kept broad to maximise search results. The
inclusion criteria consisted of full-text primary research studies
on humans which were related to the development of malignancy
in odontogenic cysts as confirmed histologically. Only studies
in English and Spanish were included as they could be reliably
interpreted by the research team. Case reports and case series
with small cohorts were permissible given the rarity of MOTs if
they extracted the minimum dataset for each patient, including
tumour site, histological diagnosis and patient treatment. On
the other hand, case series where individual patient parameters
could not be defined were not included. Similarly, in-vitro studies
or MOTs reported in animals were also excluded. Conference
abstracts or items where the full-text was unavailable were
also excluded.
All extracted data were initially stored and imported
into EndNote (Philadelphia, United States of America)
and transferred into a Microsoft Office Excel spreadsheet
(Washington, United States of America). Screening of studies
was undertaken using Covidence (Melbourne, Australia). Due
to the heterogeneity between studies, analysis was limited to
descriptive statistics. Risk of bias assessment was not deemed
necessary given most studies were anticipated to be cohort/case
series and with the rarity of MOTs and no universally agreed
treatment algorithm, the risk of bias was uncertain on almost all
reported cases and quality of evidence low. The data extraction
form was adapted from Chrcanovic et al. [13].
The terms malignant ameloblastoma, ameloblastic carcinoma
and metastasizing ameloblastoma have been used inconsistently
and somewhat interchangeably in literature. For data extraction,
TABLE 1 | Summary of the search strategy.
ID Key word Search
results
1 Odontogenic carcinoma 365
2 Malignant ameloblastoma 227
3 Metastasising ameloblastoma 2
4 Metastasizing ameloblastoma 40
5 Ameloblastic carcinoma 32
6 Sclerosing odontogenic carcinoma 36
7 Primary intraosseous carcinoma 140
8 Primary intraosseous squamous cell carcinoma 87
9 Malignant variants of odontogenic tumours 0
10 Malignant changes in odontogenic cysts 0
11 Odontogenic cyst malignancy 0
12 Clear cell odontogenic carcinoma 165
13 Ghost cell odontogenic carcinoma 64
14 Malignant keratocyst 0
15 Malignant keratocystic odontogenic tumour 0
16 Odontogenic Sarcoma 30
17 Ameloblastic fibrosarcoma 167
18 Ameloblastic odonto-dentinosarcoma 0
19 Ameloblastic odontosarcoma 16
20 Ameloblastic fibrodentinosarcoma 16
21 Ameloblastic fibroodontosarcoma 3
22 Odontogenic carcinosarcoma 18
23 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or
12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or
21 or 22
960
we adopted the authors’ reported diagnosis and acknowledged
ameloblastoma as a malignant entity (which fulfilled our
inclusion criteria) if it metastasised or was reported to have
cytological atypia, albeit these features, of themselves, are
insufficient for a definitive diagnosis ofmalignancy (this issue will
be discussed later). Data repositories, such as the Surveillance,
Epidemiology, and End Results (SEER) database use ICD-10
coding of tumours for collation of data. This has led to ambiguity
and confusion, as the ICD-10 classification does not map well
onto the WHO classification of tumours (neither 2005 or 2017),
utilising different terms and grouping entities in a different
manner [4, 14, 15]. This topic will be further developed in
the discussion.
RESULTS
The search results are outlined in Table 1 and Figure 2A. There
were 960 studies identified in the initial literature search and a
further 27 studies bymanual hand searching. Following duplicate
removal (n = 349), 638 studies had their titles and abstracts
screened by two reviewers (MD and CM) to ensure they satisfied
the inclusion and exclusion criteria. If there was any doubt at this
stage, the studies were included for full-text review. One hundred
and eight articles were excluded as they were not relevant, and
530 articles had a full-text review. Any disagreements regarding
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FIGURE 2 | (A) PRISMA flow diagram. Two hundred and eighteen articles were excluded with the following reasons: full text not available (n = 103), no treatment
details (n = 29), no primary data (n = 20), conference abstract only (n = 18), unable to extract individual patient data (n = 13), insufficient clinical information (n = 12),
articles not in English or Spanish (n = 9), molecular/immunohistochemistry studies only (n = 8), no malignant odontogenic tumour present (n = 4), and non-human
cases (n = 2). (B) Frequency of publications included in this review over time with an exponential line of best fit traced.
inclusion/exclusion were resolved through discussion and the
input of a third reviewer (KH) who made the final decision. Two
hundred and eighteen articles were excluded with the following
reasons: full text not available (n = 103), no treatment details (n
= 29), no primary data (n = 20), conference abstract only (n =
18), unable to extract individual patient data (n= 13), insufficient
clinical information (n= 12), articles not in English or Spanish (n
= 9), molecular/immunohistochemistry studies only (n = 8), no
malignant odontogenic tumour present (n = 4) and non-human
cases (n= 2). In total, 312 articles were included in this systematic
review (Supplementary Material).
The 312 studies included 507 patients with an average age
of 45.8 years (range 4 months−90 years) with 63% male and
37% female. More MOTs were located in the mandible (74.3%)
compared to the maxilla (25.7%). Tobacco and alcohol intake
and previous history of malignancy were variably reported which
precluded analysis, as this would not be representative of the
included cohort.
The date of publication ranged from 1974 to 2020 with an
increase in the number of published MOT case reports and series
over time (Figure 2B).
Symptoms
Symptoms were reported for 146 patients (28.8%). The
average duration of symptoms before a malignant diagnosis
was 14.8 months (range 2 days−600 months) and included
swelling (painful or painless), paraesthesia/dysaesthesia, fever,
trismus, oral discharge, failure of healing, facial deformity and
tooth mobility.
Histological Diagnosis
The preliminary literature search identified numerous published
cases which had an initial benign histological diagnosis followed
by a subsequent recurrence or malignant transformation.
Therefore, the first and second histological diagnoses were
captured in our data collection, but this issue significantly
complicated the assessment of the literature. If the original
diagnosis remained unchanged, no second histological diagnosis
was provided. If multiple diagnoses were made, the first and
final diagnoses were recorded. In total, 60 unique diagnoses were
made with the top 10 most common malignant first histological
diagnosis presented in Figure 3 and the most common benign
first histological diagnoses (before a subsequent malignant
diagnosis) presented in Figure 4A.
With respect to the first histological diagnosis, the most
common malignant diagnosis was ameloblastic carcinoma
(25.7%), followed by primary intraosseous squamous cell
carcinoma (13.2%), clear cell odontogenic carcinoma (10.3%),
malignant ameloblastoma (5.8%), and ameloblastic fibrosarcoma
(5.3%). An initial benign diagnosis was made for 24.7% of all
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FIGURE 3 | The top 10 most common malignant first histological diagnoses. The “Other” category includes clear cell carcinoma (0.6%), adenocarcinoma NOS,
metastatic carcinoma, and undifferentiated (all 0.4%). There were 13 other malignant entities reported at the same frequency (all 0.2%).
patients. The most common initial benign diagnosis (expressed
as a percentage of all first benign diagnoses) was ameloblastoma
(42.4%), ameloblastic fibroma (20%), odontogenic keratocyst
(11.2%), adenomatoid odontogenic tumour (2.4%), dentigerous
cyst (2.4%), and osteomyelitis (2.4%). From this initial benign
diagnosis, the most common malignant neoplasms in the
second histological diagnosis were ameloblastic fibrosarcoma
(25.6%), primary intraosseous squamous cell carcinoma (20.5%),
malignant ameloblastoma (14.5%), ameloblastic carcinoma
(14.5%), and clear cell odontogenic carcinoma (9.4%). With
respect to the second definitive histological diagnosis, there
were 14 unique diagnoses made, with the top 10 presented in
Figure 4B.
With both the first and second histological diagnoses
combined, the most common diagnoses were ameloblastic
carcinoma (23.0%), primary intraosseous squamous cell
carcinoma (14.8%), clear cell odontogenic carcinoma (11.0%),
ameloblastic fibrosarcoma (9.0%) benign ameloblastoma
(7.9%), and malignant ameloblastoma (7.0%). It is of note
that whilst ameloblastomas are considered benign entities, the
aforementioned “malignant ameloblastomas” either metastasised
or were reported as malignant based on the degree of cytological
atypia. The latter cases were not called ameloblastic carcinoma
by the authors but described as ameloblastoma with high grade
morphology or with atypia inferring malignant phenotypic
changes. It is not clear in many cases why the term ameloblastic
carcinoma was not used, nonetheless cases describing a
“malignant” ameloblastoma were included as meeting the
criteria of a malignant odontogenic tumour. This is not a
homogeneous group, as the term has been variably applied,
but addressing this issue would have required detailed re-
analysis/diagnosis of every published case. To ensure clarity
in data extraction, the author’s diagnosis was recorded as
stated. Further sub-group analysis was undertaken of these
top five most common malignant diagnoses summarised in
Table 2. This was adjusted with respect to the final recorded
histological diagnosis to prevent overlapping of data. A graphic
representation for frequency site distribution of MOTs is
presented in Figure 5.
Metastasis Site
In total, 36.7% of all patients had reported metastasis. Cervical
lymph nodes were the most common site of metastasis with 9.3%
of patients having positive nodes on first presentation. A further
3.2% of patients developed cervical lymph node metastasis as
their disease progressed.
The following MOTs were reported with respect to lymph
node metastases (percentage expressed as a proportion
of all cases with lymph node metastases only); PIOSCC
(33.8%), ameloblastic carcinoma (21.6%), malignant
ameloblastoma (16.2%), clear cell odontogenic carcinoma
(14.9%), squamous cell carcinoma (4.1%), and ghost cell
odontogenic carcinoma and ameloblastic fibrosarcoma (both
2.7%), and spindle cell carcinoma, ameloblastic fibrosarcoma
and malignant calcifying epithelial odontogenic tumour
(all 1.4%).
The lungs were the most common organ to be affected by
distant metastasis affecting 11.2% of all patients (Figure 6).
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FIGURE 4 | (A) The most common benign first histological diagnosis. The “other” category includes unspecified odontogenic cyst, calcifying epithelial odontogenic
tumour, cemento-ossifying fibroma, inflammation/infection post tooth-extraction, squamous odontogenic tumour, and pleomorphic adenoma with all with the same
frequency (1.6%). There were 17 other diagnoses made with a range of conditions such as unspecified ameloblastic tumour and unspecified benign odontogenic cyst
which were all reported at the same frequency (0.8%). (B) Top 10 most common second histological diagnosis. The “other” category includes ameloblastic
fibro-odonto sarcoma, odontogenic carcinosarcoma (both 1.3%) and ameloblastic dentinosarcoma, malignant Pindborg tumour and calcifying epithelial odontogenic
tumour (all 0.6%). It is of note, regarding the case of calcifying epithelial odontogenic tumour, one was diagnosed as a malignant variant and one case was diagnosed
as a clear cell odontogenic carcinoma initially however this diagnosis was revised to the aforementioned on the resection.










Mean age (years, with range) 53.1 (6–84) 38.6 (8–75) 55.9 (25–89) 27.3 (0.3–83) 45.6 (2–90)
Sex ratio (M:F) 67:28 11:6 14:23 35:23 33:16




















Surgery (neck dissection) 98.9% (54.0%) 98.0% (16.3%) 94.4% (29.2%) 98.2% (5.3%) 97.1% (21.0%)
Chemotherapy 14.9% 12.2% 6.9% 17.5% 5.1%
Radiotherapy 37.9% 14.3% 23.6% 24.6% 26.1%
Chemotherapy and radiotherapy 5.7% 2.0% 0.0% 1.8% 1.4%
Surgery and chemotherapy 13.8% 12.2% 2.8% 15.8% 3.6%
Surgery and radiotherapy 37.9% 14.3% 23.6% 24.6% 25.4%
The diagnosis was only included in the analysis if it was the final diagnosis stated by the authors. Patients who declined treatment were removed from final treatment analysis.
Subgroup analysis of patients with lung metastasis determined
that the most common histological diagnosis (including
1st and 2nd histological diagnoses; adjusted by removing
the first histological diagnosis if changed from benign
to malignant) was malignant ameloblastoma (40.0%),
ameloblastic carcinoma (29.1%), clear cell odontogenic
carcinoma (12.7%), primary intraosseous squamous
cell carcinoma and ameloblastic fibrosarcoma (both
5.5%). In total, there were 23 sites for MOT metastasis
(Figure 6).
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FIGURE 5 | Graphic representation for frequency of site distribution (by jaw only: mandible or maxilla) of the most common combined first and second malignant
histological diagnosis. PIOSCC, primary intraosseous squamous cell carcinoma; Am, malignant ameloblastoma; CCOC, clear cell odontogenic carcinoma; AFS,
ameloblastic fibrosarcoma; AC, ameloblastic carcinoma; N.B, This diagram only illustrates tumour frequencies in the mandible and maxilla, further information for sub
site/laterality was not available.
Recurrence
Across all MOTs, 26.8% of patients developed recurrence.
Subgroup analysis of this cohort identified the average patient
age at 45.2 years (range 5–89 years) with 67.6% male and 32.4%
female. The mandible was the most common site, affecting 77.6%
of patients with the maxilla affecting 22.4%.
Expressed as a percentage of all recurrent cases, the
most common first histological diagnosis was ameloblastic
carcinoma (26.1%), malignant ameloblastoma (19.6%) (benign
ameloblastoma was recorded at 10.9%), followed by clear
cell odontogenic carcinoma (8.7%), primary intraosseous
squamous cell carcinoma (6.5%) and ameloblastic fibroma
(5.8%). The most common second histological diagnosis was
ameloblastic fibrosarcoma (24.5%), ameloblastic carcinoma
(20.4%), malignant ameloblastoma (18.4%) and clear cell
odontogenic carcinoma (12.2%).
Treatment
The most common treatment undertaken was surgical resection
of the lesion (87.2%). Some patients also had a neck
dissection (25.2%), chemotherapy (9.7%), and radiotherapy
(25.6%); these adjuvant treatments were also used however
this cohort also included palliative care patients. Enucleation
(1.2%) and curettage (3.6%) were also treatments undertaken
however for nearly all of such cases, it was not known at
that stage if the lesion was malignant or would transform
into malignancy.
Genetics
Fifteen studies undertook some form of genetic analysis on their
tumour samples. BRAF p.V600E mutations were identified in
five of seven tested ameloblastic fibrosarcoma cases. However,
immunostaining of the mutant BRAF protein was reported to
be unreliable. In the same report, one ameloblastic fibrosarcoma
showed a NRAS p.G61K mutation which was mutually exclusive
with BRAF [16]. This was supported by another case study of a
patient with BRAF p.V600E mutation in the initial ameloblastic
fibroma and also in the subsequently transformed ameloblastic
fibrosarcoma [17]. In clear cell odontogenic carcinoma (CCOC),
EWSR1 and ATF1 probes have been used to successfully
identify gene rearrangements [18–20]. In contrast, sclerosing
odontogenic carcinoma was shown to be consistently negative for
EWSR1 rearrangements [21–24]. Regarding numerical genetic
abnormalities, one case of CCOC had a DNA-Index of 1.93% and
an S-Phase of 10.2% [25]. Moreover, in CCOC another article
reported gains in chromosomes 14, 19 and 20; and losses in
chromosome 9, whereas in the pulmonary metastatic lesions the
losses were in chromosome 6 [26].
Sequencing with a mutational panel of two odontogenic
carcinomas with dentinoid demonstrated 19 variants in 13 genes.
The variants with reported pathological significance were a non-
sense variant of APC and missense variant of CTNNB [27]. A
CTNNB1 mutation was also identified in a case of ghost cell
odontogenic carcinoma [28].
Whole-exome sequencing for a metastasising ameloblastoma
demonstrated 7 somatic mutations which included BRAF,
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FIGURE 6 | (A) Representation of the most common sites of metastasis. Percentages are expressed to only reflect patients who have had metastases. Patients with
no recorded metastasis are not included in this calculation. The “other” category includes the thyroid, kidneys, non-cervical lymph nodes, and cranial nerves (all 1.1%)
and salivary glands, pharynx, orbit, larynx, intestines, heart, branchial plexus, carotid bifurcation, and unspecified distant metastasis (all 0.5% respectively). (B) Graphic
representation of the most common MOTs metastasising to distant sites (from left to right: lungs, brain, skull, liver and skin–mediastinum was not included in the
diagram). With metastasis to the lung, ameloblastic fibrosarcoma (n = 2), squamous cell carcinoma (n = 2), unspecified odontogenic biphasic malignant neoplasm (n
= 1), and unspecified odontogenic carcinoma (n = 1) were also recorded but not shown in the diagram. With metastasis to the brain, clear cell odontogenic
carcinoma and unspecified odontogenic carcinoma were both recorded (both n = 1) but also not shown in the diagram. Created with BioRender.com.
MYCN, MLL2, ARIDIA, MLL2, RUNX1, and ASXL1 and no
germline mutations. Microsatellite status was also reported as
stable with low tumour mutation load (7.0 mutations/Mb) [29].
In ameloblastic carcinoma, aberrant CpG island methylation of
p16 was identified however there were no mutational alterations
in p53 exons 5–8 [30].
Genetic sequencing did not identify a Patched 1 mutation in
a patient with PIOSCC as part of their investigation into basal
cell nevus syndrome [31] which has been reported in this review
for completeness.
DISCUSSION
MOTs are a heterogeneous group of lesions that arise from the
epithelial and/or mesenchymal remnants of the tooth germ or
from a pre-existing odontogenic lesion such as a benign OT or an
odontogenic cyst [11]. Due to their low incidence, they remain
poorly understood entities with respect to their cancer biology,
clinical behaviour, management and long-term prognosis [1, 11,
32]. In addition, their histopathological features significantly
overlap with their benign counterparts, increasing the difficulty
for the pathologist to reach a diagnosis, and with significant
potential for misdiagnosis [3, 32]. Regarding the management
of MOTs, surgical excision has been reported as the mainstay of
treatment, however this review has highlighted variable use of
adjuvant chemo/radiotherapy and neck dissections.
This review showed that MOTs are more common in males,
have a strong predilection for the mandible and present in
patients with an average age of 45.8 years. Similar to our findings,
a retrospective analysis of 308 MOTs in the United States
reported a median age range at diagnosis of 50–54 years with a
slight male predominance [14]. In general terms, these findings
are in agreement with the demographic features of benign OTs
(excluding hamartomas such as odontoma, or tumours that
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are more commonly diagnosed during the first two decades
of life such as adenomatoid odontogenic tumour, unicystic
ameloblastoma and ameloblastic fibroma) [33]. The exception
to this trend in the case of MOTs is GCOC, which has a
maxilla:mandible ratio of 2:1 [34, 35].
The current 2017 WHO Classification of Head and Neck
tumours describes a range of MOTs, namely: ameloblastic
carcinoma (AC), primary intraosseous carcinoma, NOS (PIOC),
sclerosing odontogenic carcinoma, clear cell odontogenic
carcinoma (CCOC), ghost cell odontogenic carcinoma (GCOC),
odontogenic carcinosarcoma and odontogenic sarcomas
[11]. This list has evolved over the various iterations of the
WHO classification.
Diagnosis, Terminology, and Classification
The diagnosis of malignant odontogenic tumours is challenging
and requires clinical, radiological and histological data to
make a definitive diagnosis of malignancy. We have found
that for many cases in the literature this full set of data
is not presented, making detailed assessment of the accuracy
of diagnosis very difficult. Furthermore, applying the usual
defining criteria for malignancy (invasion, metastasis and other
cytological/histological features, which are at times rather vague
and exist on a spectrum) in isolation to odontogenic lesions
may result in overdiagnosis. There are several reasons for this,
pertinent to the particular context in which odontogenic tumours
arise. For example, benign tumours, such as ameloblastoma, may
widely infiltrate the medullary cavity of the jaw bones and can
infiltrate soft tissue. The presence of perineural spread causes
diagnostic difficulty as the fact that odontogenic epithelium
normally lies in close proximity to nerves must be considered.
Furthermore, the presence of cytological atypia in some lesions
(more common in the maxilla, largely within the spectrum
of benign lesions) raises the issue of which features, and
what degree of cytological atypia are associated with malignant
behaviour clinically and on imaging. These are important
considerations as, in many cases, the diagnostic issues arise in
the differentiation from benign tumours. Furthermore, reported
deaths from odontogenic tumours do not support a diagnosis
of malignancy per se, as, for example, inadequate treatment of
a maxillary ameloblastoma may result in infiltration of the skull
base and infratemporal fossa. Unfortunately, these crucial issues
are mentioned only in passing in a small proportion of the
literature we have examined.
The evaluation of literature in this systematic review has
demonstrated the variable and interchangeable use of the
terms malignant ameloblastoma, ameloblastoma with atypia or
high-grade features, ameloblastic carcinoma and metastasizing
ameloblastoma, which compounds the difficulties in making
and reviewing the diagnosis. In the 1971 WHO classification
of odontogenic tumours, cysts and allied lesions [36], the
term “malignant ameloblastoma” included all neoplasms with
ameloblastoma-like features in the primary and metastatic
growth, regardless of cytological features of malignancy [36].
Subsequently, in 1974, Shafer and colleagues introduced the
term “ameloblastic carcinoma” referring to a well-differentiated
ameloblastoma with malignant transformation of the epithelial
component. A decade later in 1984, Slootweg and Muller
[37] highlighted that the WHO definition of “malignant
ameloblastoma” was confusing and proposed that the term
“malignant ameloblastoma” should be reserved for lesions
that metastasise, despite their well-differentiated appearances;
whereas ameloblastic carcinoma should describe lesions that
combine features of ameloblastoma with less-differentiated
areas (regardless of their histogenesis; encompassing de novo,
malignant transformation from an ameloblastoma or from an
odontogenic cyst) [37]. The WHO 1992 classification continued
to use the term “malignant ameloblastoma”; however the
definition was clearer in terms of the histologic features, which
included any lesion with features of an ameloblastoma with
cytological features of malignancy in the primary tumour in
the jaws and/or any metastatic growth, regardless of their
pathogenesis (primary malignant or malignant transformation of
a pre-existing ameloblastoma) [38].
The WHO 2005 classification made significant changes to
the classification of malignant odontogenic tumours which were
mainly centred on the histogenesis of the lesion [40]. This version
includedwithin the odontogenic carcinomas groupmetastasizing
ameloblastoma (a histologically benign ameloblastoma that
metastasizes) and defined three subtypes of ameloblastic
carcinoma, the first referred to the primary type as corresponded
to an ameloblastic carcinoma that arises de novo and, two
secondary subtypes that arise in a pre-existing ameloblastoma
(intra or extraosseous). The term “malignant ameloblastoma” was
not used. The current WHO classification (2017) simplified the
classification, prioritising the histomorphology above the origin
and biological behaviour, leaving out any unproven references to
histogenesis or precursor lesions [11]. Ameloblastic carcinoma
was included in the odontogenic carcinoma subgroup, referring
to the malignant counterpart of an ameloblastoma; whereas
metastasizing ameloblastoma was removed from the malignant
group and included in the benign epithelial odontogenic tumours
group and defined as an ameloblastoma that metastasizes despite
its benign histological features [11], making the terminology
consistent with metastasising pleomorphic adenoma and other
benign conditions with distant spread. However, Reichart et al.
[41] have suggested that the current classification has been
oversimplified, as they see no clear justification for classifying
metastasizing ameloblastoma within the benign group, as it has
a 70% 5-year survival.
The SEER database allows the analysis of large cohorts
of data contributing to the understanding of these rare
malignancies, nonetheless, one of its limitations is the lack
of a centralised pathology review and therefore, there is a
possibility of ambiguous sub-classification and misdiagnosis [4,
15]. As mentioned before, the SEER database (in common
with many others) follows ICD-10 coding of tumours. The
ICD-10 classification does not map well onto the current
WHO classification of tumours, and still utilises the general
term malignant odontogenic tumour (9270/3) as one of the
main diagnostic codes. Currently, this includes ameloblastic
carcinoma, PIOSCC and sclerosing odontogenic carcinoma. The
code for malignant ameloblastoma has been retained (9310/1)
and is presented as a synonym for metastasising ameloblastoma.
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Whilst the individual diagnostic categories do appear to be
accessible in recent SEER data, this level of granularity was not
available in the 1973–2011 data reported by Lee et al. [4] and
Agarwal et al. [14]. This poses a difficulty as it is likely that the
categories reported in these large series are almost certainly a
mixture of a number of different entities, with varied clinical
courses and outcomes. In particular, the continued use of the
term “malignant ameloblastoma,” which was defined in the 1972
and 1992 WHO classifications, but which now is depreciated
terminology, has resulted in confusion in the literature, as
evidenced by the large number of cases of “ameloblastoma with
atypia and/or metastases” for which this term has been used,
in preference to ameloblastic carcinoma. Given this, the group
probably contains a mixture of benign (Am) and malignant
(AC) lesions with no certainty as to the proportion which are
truly malignant. This has a direct impact on the prevalence of
“malignant ameloblastoma,” which has been estimated to be 60%
of MOTs in two different reports, although a high percentage of
these cases did not metastasise [4, 14].
In order to achieve consistency, the following classification of
epithelial odontogenic tumours containing epithelium with the
histological pattern of ameloblastoma (at least focally), which is
essentially a restatement of the 2017 WHO classification, should
be used:
1. Ameloblastomas are considered benign if they have no
clinical, radiological or histological features suggestive of
malignancy, including no evidence of cytological atypia,
malignant transformation or metastasis.
2. Cytologically and otherwise clinically/radiographically benign
ameloblastomas which metastasise. The benign appearance
must be present in both the primary tumour and the
metastasis. The survival data presented in the case series by
Slootweg and Muller [37] has been used to suggest that this
should be considered as a distinct entity and not classified
with benign ameloblastoma, but there is insufficient evidence
to define this as a malignant neoplasm. If future molecular
studies indicate that metastasising ameloblastoma has similar
genetic aberrations to non-metastasising ameloblastoma or
to ameloblastic carcinoma, then that may be the time to
consider a change in the classification. At present this should
be separately classified as metastasising ameloblastoma.
3. Tumours with clinical, radiological and histological features of
malignancy and histological pattern of ameloblastoma should
be termed ameloblastic carcinoma, regardless of the presence
of metastases. Histological features alone are insufficient for
this diagnosis. In some cases, in a pre-existing ameloblastoma,
this may be very focal, and whilst the term “in situ”
ameloblastic carcinoma has been suggested, there is currently
no literature to support this concept, or any indication that
tumours with only focal malignant change behave differently
from a benign lesion. The pathogenesis (i.e., from a benign
OT or de novo) may be interesting to note, but there is little
evidence that this has a bearing on clinical behaviour.
At present, there is limited genetic research into the components
of this family of MOTs, although some data is appearing from
ameloblastic carcinomas [40, 42]. Further insight into each
of the main subgroups as described will help elucidate key
biological events that identify tumours at risk of malignant
transformation and risk of metastasis and further improvements
in prognostication and standardisation in treatment algorithms.
A diverse range of names, without clear definitions, is likely to
hinder research progress and as demonstrated in this review,
complicate consolidation of published evidence.
In the present review, the most common second histologic
diagnosis was ameloblastic fibrosarcoma (AFS). Regarding
this entity, the classification for odontogenic sarcomas has
been simplified from 2005 to 2017, and currently it covers
a group of mixed odontogenic tumours in which only the
mesenchymal component shows malignant cytological features
[11]. The former classification included AFS, ameloblastic
fibrodentinosarcoma and ameloblastic fibro-odontosarcoma,
and whilst these remain as subtypes, the clinical relevance of this
subclassification has been called into question [43]. A recently
published series of seven cases of AFS, reported that four of
these showed evidence of a pre-existing benign precursor such
as ameloblastoma or ameloblastic fibroma [16]. The authors
stated that no recurrences, metastases, or deaths were seen with
a median follow-up of 37 months, however 2 patients were
lost to follow-up post-surgery. However, our review found that
12.5% of AFS cases had an initial histological misdiagnosis,
many of which were AF, but this also included ameloblastoma
and other unspecified odontogenic tumours. The variety of
initial diagnoses, some without an odontogenic mesenchyme
component raises the issue of misdiagnosis (see later). In these
tumours the stromal component should be carefully assessed in
order to differentiate mature fibrous tissue from an immature
mesenchyme that resembles dental papilla [44]. Given that a large
proportion of the reported cases of AFS occur in young adults
and children, this is a major potential pitfall, in which lesions
which are not neoplastic may be mistaken by the inexperienced
pathologist for benign or even malignant mixed odontogenic
tumours. Again, it is important to restate that the clinical,
radiological and histological features must all be considered
before a diagnosis of AFS is made.
In the 2005 WHO classification, PIOSCC was divided into a
solid type, those derived from keratocystic odontogenic tumour
and a third group derived from odontogenic cysts, nevertheless
in the current classification it is represented by a single entity
termed Primary intraosseous carcinoma [PIOC (NOS)]. The
removal of subtypes and simplification is likely to represent no
change in treatment or clinical outcomes with either subtype
[43, 45].
In relation to other odontogenic malignancies, a new entity
of Sclerosing Odontogenic Carcinoma was added to the WHO
Classification of Head and Neck Tumors (2017). There have
been 14 cases published to date [46]. Features such as perineural
invasion were cited to support its recognition as a malignant
tumour, however it has a low mitotic activity and no metastases
have been reported to date [46]. Indeed, the diagnostic criteria for
this entity are still somewhat vague.
In addition, the current WHO (2017) classification included
odontogenic carcinosarcoma (OCS). This was described in the
1992 classification and then excluded from the 2005 classification
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[38, 39]. This is an extremely rare and aggressive entity,
characterised by epithelial and mesenchymal components with
cytologically malignant features, with a high positivity for p53
(90%) and Ki67 proliferation index (45%) in both components
[47]. A systematic review showed 9 cases of OCS, from which
only 1 in 5 arose de novo and the remaining were derived
from a pre-existing lesion such as ameloblastoma, ameloblastic
fibroma and a cementomatous/osteoblastic lesion [48]. As with
other entities within the group of MOTs, the pathogenesis of
its malignant transformation remains unclear, however multiple
recurrences have been reported [49]. Recurrence of OCS has been
highly reported in literature with 50% of the patients having
metastasis (lungs, lymph nodes, ribs and pelvis) and 57% of the
patients succumbing to this malignancy [48].
Histological Misdiagnosis
Histological misdiagnosis was either directly reported by the
authors of the original case or interpreted by the authors of this
review during full text analysis in some cases. The latter included
an immediate change in diagnosis on review of the sample,
clinical progression/deterioration following a benign diagnosis,
with subsequent confirmation of a malignant counterpart in the
same site or the authors stating a clear MOT was diagnosed and
on review of the initial biopsy, the same features were identified
even if more subtle. One study has reported that only nine
of 22 reported MOTs were actually considered malignant on
review [1], which is concerning, and is somewhat supported by
the balance of this literature review. Unfortunately, it is likely
that misdiagnosis will be frequent, considering that odontogenic
tumours are rare, expertise is limited, and definitions varied.
An important factor to consider during the diagnosis of OTs
is the interpretation of incisional biopsies, which may not be
representative of the entire lesion. Caution in the diagnosis needs
to be communicated to the clinical team if they have provided an
incisional biopsy that may not be representative, as, for example,
ameloblastomas, even with a benign appearance, form a high
proportion of OTs cases that have distant metastasis.
Clinicopathological and radiological correlation is essential
in the diagnosis of a MOT, and the use of molecular markers
may be helpful in addition to this. Within the clinicopathological
features, larger lesions, rapid destructive growth, lymph node
metastases and older patients are some of the clinical features that
are consistent with malignancy [50]. Correspondingly, benign
OTs such as ameloblastoma and calcifying epithelial odontogenic
tumour (CEOT) are infiltrative and destructive lesions and may
be confused with a MOT based on clinical behaviour. At the
microscopic level, cellular crowding and budding, nuclear and
cellular pleomorphism, high proliferation rates, focal necrosis
and perineural or vascular infiltration represent highly suspicious
features of malignancy [1, 44, 50]. Again, there is an overlap
with benign OTs: tumours such as CEOT and some maxillary
ameloblastomas can show some of these histological features in
spite of their benign nature [50].
Ki67 may be useful for the differentiation between
ameloblastoma and ameloblastic carcinoma. Hunter and
Speight suggested that Ki67 expression in more than 20% of
the epithelial cells may be consistent with the diagnosis of
ameloblastic carcinoma, but this has to be interpreted in the
context of the other clinical, radiological and histological features
[44]. Other markers, such as SOX2 and OCT4 expression, have
also been suggested [51]. To date there is no convincing evidence
that the use of immunostaining surpasses histopathology
alone. Instead, morphology, immunostaining and cytogenetic
techniques should complement each other for diagnosis,
especially when the proliferation rate and the presence of cell
variants are ambiguous.
In addition, tumours with clear cells, such as CCOC and
clear cell variants of intraosseous mucoepidermoid carcinoma
and ameloblastic carcinoma, have been shown to lack features
of cytological atypia leading to misdiagnosis [50]. Therefore,
caution must be exercised during histopathological assessment
especially in tumours with ameloblastoma-like epithelium
in terms of their proliferation rate, tumours with mixed
components and clear cell tumours. For the latter, PAS+/-
Diastase and Alcian blue may be used to rule out mucin or
glycogen accumulation; with immunostaining for RCC/CD10
and S100/SOX10 helpful to rule out renal carcinoma and
melanoma, respectively [50].
Treatment
In the literature examined, there is general agreement that
MOTs should be treated with surgery but this review highlights
variable use of adjuvant therapy and neck dissections. Within the
spectrum of MOTs, the range of aggressiveness of the malignant
process varies, and this is reflected in the varied treatment
approaches. Under ‘surgery’ we included not only marginal
and segmental resections, but also enucleation and curettage
in specific cases. Neck dissection was performed in half of all
PIOSCC cases and 30% of CCOC cases. In the case of AFS, only
5.3% of the patients had a neck dissection. The combination of
surgery and radiotherapy was performed in 37.9% of PIOSCC
and 25.4% of ameloblastic carcinoma cases. In the same way,
the combination of surgery and chemotherapy was conducted in
15.8% of AFS cases and 13.8% of PIOSCC cases. A survival study
of patients with MOTs showed that patients who were not treated
with radiotherapy were almost 20 times more likely to die [14].
The most common site of metastasis reported were the
cervical lymph nodes which raises the issue of the need for
a concurrent neck dissection during surgical resection. In this
review, we found that 9.3% of the patients had positive lymph
nodes on first presentation. This is within a similar range to the
seventeen percent reported by Agarwal et al. [14]. This review
has highlighted that the majority of lymph node metastasis from
MOTs occur from PIOSCC, malignant ameloblastoma and clear
cell odontogenic carcinoma (accounting for a combined 86.5% of
all lymph node metastases). Ameloblastic fibrosarcoma was only
involved in 2.7% of all lymph node metastases however made
up 21.2% of all second histological diagnoses. Further work is
required to produce standardised treatment algorithms including
concurrent neck dissections.
The challenge arises given that many MOTs are diagnosed on
resection rather than the initial biopsy (Table 2): however, re-
operating to achieve optimum surgical margins should include
consideration of the need for a neck dissection. There is, however,
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no data to support this as a routine procedure in a clinically N0
neck, and such a case would benefit from multidisciplinary team
input into the decision-making process.
Distant organ metastasis (DM) most commonly affected the
lungs (30.6% of DM patients), followed by the brain (7.5%),
mediastinum and bone (both 3.8%), liver (3.2%), skull (2.7%),
and spine and skin (both 2.2%). Lung involvement was in
keeping with what has been previously reported for metastasising
ameloblastoma [52], ameloblastic carcinoma [9] and CCOC [10].
A retrospective analysis reported only 4% (13/308) of MOTs with
distant metastasis at the time of the first diagnosis [14].
Recurrence and Survival
We report that 26.8% of patients with MOTs developed
recurrence with ameloblastic carcinoma and lesions described
as malignant ameloblastoma are the most common recurring
tumours. Recurrences have been reported in 28% of ameloblastic
carcinomas [53], whereas a recent review of CCOC reported
that this tumour has a recurrence rate of 38 of 88 (43%) cases
[54]. Huang et al. reported that for PIOSCC, the probability of
recurrence is related to lymph node metastasis and treatment
undertaken, with a 55.6% recurrence rate at 2 years [55].
In terms of survival rates, based on the information
from the SEER database, Agarwal et al. [14] reported that
patients diagnosed with malignant ameloblastoma had a better
survival rate than patients with other “malignant odontogenic
tumours” (which included odontogenic carcinomas, PIOSCC
and ameloblastic carcinoma, as noted earlier), or AFS [14].
The latter showed the lowest 5-year survival rate of 44.4%
compared to the 86.5% seen in malignant ameloblastoma [14].
Increasing age at diagnosis, lack of radiation treatment after
surgery, increasing tumour size, and AFS histopathology were
each found to exert a statistically significant negative impact on
survival [14]. As stated earlier, it was not possible to make clear
conclusions regarding survival from this systematic review.
Molecular Pathology
The molecular mechanisms underpinning MOT development
remain poorly understood, mainly due to the rarity of these
lesions and thus the difficulty of collating large cohorts with
follow-up that allows robust conclusions in terms of clinical
behaviour, outcome, and prognosis. For this reason, to date
it has not been possible be establish the significance of the
genetic/epigenetic alterations that have been reported in these
tumours. Despite this, interesting findings have been reported
about the genetic profile of some of these MOTs. Ameloblastic
carcinomas, as also seen in their benign counterparts, often
harbour the BRAF p.V600E mutation, however in a lower
frequency that ranges from 23 to 33% [40, 56, 57]. This mutation
has been demonstrated in other tumours with ameloblastic
morphology such as ameloblastic fibromas and ameloblastic
fibro-odontomas [56]. Likewise, it was recently reported that the
presence of the same mutation in BRAF in 5 of 7 ameloblastic
fibrosarcomas (AFS) [16] and also in a rare and aggressive form
of AFS [17]. Moreover, it was shown in one AFS that both the
epithelial and mesenchymal components harboured the BRAF
p.V600Emutation [16].
A case diagnosed as malignant ameloblastoma showed
7 somatic mutations which included BRAF, MYCN, MLL2,
ARIDIA, MLL2, RUNX1, and ASXL1. However, no further
analysis was undertaken to determine which of these mutations
serve as oncogenic drivers or passengers or if these mutations
acted variably in timing of effect during tumour development
[29]. The patient, who had brain and lung metastasis, received
combined chemotherapy including Adriamycin, ifosfamide, and
dacarbazine and showed a 90% of reduction in the lung
metastases after 6 cycles; however, there was no long-term follow-
up [29].
CCOC have a rearrangement of EWSR1 in more than
80% of cases [11], similar to clear cell carcinoma of the
salivary glands. Both entities not only share morphological
similarities, but also the EWSR1–ATF1 gene fusion [20]. In
other cases, the EWSR1–CREB1 fusion has been demonstrated
[58]. Although the identification of EWSR1–ATF1 may be useful
for the differential diagnosis between CCOC and other clear
cell tumours, any significance for the treatment-decision and
prognosis is still unclear.
Regarding GCOC, only 51 cases have been reported to date
[35]. Genetic alterations in GCOC have been reported for
CTNNB1 p.S33C,CREBBP p.K1741∗, andMLL2 p.S1997fs∗4 [59].
Whole-genome sequencing was performed by Bose et al. [60] on
a single case, in which copy number gains were reported at SHH,
GLI1, JAG1, DTX3, andHEY1, whereas gene fusions were seen at
TCF4 and PTPRG. On the other hand, an article which included
2 GCOCs among other OTs, reported that BRAF p.V600Ewas not
present in these two cases [61].
Furthermore, MOTs with putative driver mutations, such
as BRAF for tumours with ameloblastoma-like epithelium
and EWSR1 for tumours highly suspicious of being CCOC,
should be considered candidates for mutation assessment.
In recent years, a few cases of targeted treatment using
BRAF-inhibitor monotherapy (vemurafenib) or combination
of BRAF-MEK inhibitors (dabrafenib and trametinib) for
ameloblastoma (mainly recurrent or metastasising) have been
published [62–66]. These reports showed important size
reduction of the tumours and no recurrence during their
follow-up (around 30–56 weeks). A common finding among
these case reports is the apparent lack of resistance of the
tumour towards the therapy (compared to what has been seen
in melanoma).
CONCLUSION
MOTs are a rare, complex and heterogeneous group of
tumours with evolving insight into their genetic profiles and
classification. There is significant overlap, both histologically
and molecularly with normal tooth development and benign
odontogenic tumours [67], thus it has been a challenge for
pathologists to establish criteria for diagnosis, with appropriate
consistent terminology and classification. As aforementioned,
their pathogenesis remains unclear, especially in cases where
malignant transformation in a benign lesion has apparently
taken place. This review has consolidated the extensive case
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report-dominated literature and highlighted areas for future
research, but the main areas of challenge remain: application
of a clear definition of malignancy and the consistent use
of terminology. This would be aided by the diagnosis and/or
review of all odontogenic tumours within specialist centres.
Furthermore, it would be a huge challenge, but with a
great impact in the improvement of the biological data
within SEER and other databases (such as the DOSAK
tumour register), to undertake a retrospective pathology review
of the tumours following clarification of terminology and
improvement/rationalisation of ICD coding. This will be aided
by establishment of an expert consortium to map crucial
clinical, radiological and histological features to the molecular
changes using “omics” techniques which will help define
benign and malignant OTs. A deeper understanding of the
molecular background of odontogenic lesions will allow the
establishment of a new classification system that brings together
the genotypic and phenotypic features of these lesions, in
order to improve nomenclature that fits both histology and
clinical behaviour, opens avenues for targeted therapy and
better prognostication.
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